Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy ContraFect Corporation stock | $3.83

Learn how to easily invest in ContraFect Corporation stock.

ContraFect Corporation is a biotechnology business based in the US. ContraFect Corporation shares (CFRX) are listed on the NASDAQ and all prices are listed in US Dollars. ContraFect Corporation employs 33 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in ContraFect Corporation

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CFRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ContraFect Corporation stock price (NASDAQ: CFRX)

Use our graph to track the performance of CFRX stocks over time.

ContraFect Corporation shares at a glance

Information last updated 2021-10-24.
Latest market close$3.83
52-week range$3.10 - $7.30
50-day moving average $3.94
200-day moving average $3.97
Wall St. target price$13.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.44

Buy ContraFect Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ContraFect Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ContraFect Corporation price performance over time

Historical closes compared with the close of $3.83 from 2021-10-22

1 week (2021-10-18) -0.26%
1 month (2021-09-24) -4.49%
3 months (2021-07-23) -3.04%
6 months (2021-04-23) -7.26%
1 year (2020-10-23) -28.68%
2 years (2019-10-25) 1,183.08%
3 years (2018-10-25) 104.81%
5 years (2016-10-25) 58.92%

ContraFect Corporation financials

Gross profit TTM $-1,606,434
Return on assets TTM -31.96%
Return on equity TTM -37.79%
Profit margin 0%
Book value $1.46
Market capitalisation $150.6 million

TTM: trailing 12 months

Shorting ContraFect Corporation shares

There are currently 2.9 million ContraFect Corporation shares held short by investors – that's known as ContraFect Corporation's "short interest". This figure is 7.6% down from 3.2 million last month.

There are a few different ways that this level of interest in shorting ContraFect Corporation shares can be evaluated.

ContraFect Corporation's "short interest ratio" (SIR)

ContraFect Corporation's "short interest ratio" (SIR) is the quantity of ContraFect Corporation shares currently shorted divided by the average quantity of ContraFect Corporation shares traded daily (recently around 128425.39335664). ContraFect Corporation's SIR currently stands at 22.88. In other words for every 100,000 ContraFect Corporation shares traded daily on the market, roughly 22880 shares are currently held short.

However ContraFect Corporation's short interest can also be evaluated against the total number of ContraFect Corporation shares, or, against the total number of tradable ContraFect Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ContraFect Corporation's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 ContraFect Corporation shares in existence, roughly 70 shares are currently held short) or 0.0921% of the tradable shares (for every 100,000 tradable ContraFect Corporation shares, roughly 92 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against ContraFect Corporation.

Find out more about how you can short ContraFect Corporation stock.

ContraFect Corporation share dividends

We're not expecting ContraFect Corporation to pay a dividend over the next 12 months.

Have ContraFect Corporation's shares ever split?

ContraFect Corporation's shares were split on a 1:10 basis on 3 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ContraFect Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for ContraFect Corporation shares which in turn could have impacted ContraFect Corporation's share price.

ContraFect Corporation share price volatility

Over the last 12 months, ContraFect Corporation's shares have ranged in value from as little as $3.1 up to $7.3. A popular way to gauge a stock's volatility is its "beta".

CFRX.US volatility(beta: 0.87)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ContraFect Corporation's is 0.8651. This would suggest that ContraFect Corporation's shares are less volatile than average (for this exchange).

ContraFect Corporation overview

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. The company has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. It also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. The company was incorporated in 2008 and is headquartered in Yonkers, New York. .

Frequently asked questions

What percentage of ContraFect Corporation is owned by insiders or institutions?
Currently 4.871% of ContraFect Corporation shares are held by insiders and 63.945% by institutions.
How many people work for ContraFect Corporation?
Latest data suggests 33 work at ContraFect Corporation.
When does the fiscal year end for ContraFect Corporation?
ContraFect Corporation's fiscal year ends in December.
Where is ContraFect Corporation based?
ContraFect Corporation's address is: 28 Wells Avenue, Yonkers, NY, United States, 10701
What is ContraFect Corporation's ISIN number?
ContraFect Corporation's international securities identification number is: US2123263004
What is ContraFect Corporation's CUSIP number?
ContraFect Corporation's Committee on Uniform Securities Identification Procedures number is: 212326102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site